Carnegie Mellon University Technology Transfer Office
This article was originally published in Start Up
Executive Summary
The same model CMU has used successfully in high technology (it incubated the search engine company, Lycos Inc.) can be applied to biomedical start-ups. But because development timeframes are much longer, meaning that more resources must usually be applied to maximize the probability of success, CMU doesn't expect to form that many biomedical enterprises.
You may also be interested in...
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.
Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.